Mirtazapine and Vitamin B6 May Be Best Options for Antipsychotic-Induced Akathisia
APA ’s Good Faith Estimates Survey: Please Respond TodayThe No Surprises Actrequires clinicians to provide patients who are uninsured or are insured but choose not to submit claims through their health plan with a Good Faith Estimate of the cost of care. The Centers for Medicare and Medicaid Services has asked APA for your feedback on efforts to comply with these requirements and any educational support you may need from CMS. The deadline istoday, March 8.TAKE SURVEYAkathisia —a feeling of restlessness that is often accompanied by movements like rocking or pacing—is a common side effect of antipsychotic medications. ...
Source: Psychiatr News - March 8, 2024 Category: Psychiatry Tags: akathisia antipsychotic JAMA Network Open meta-analysis mirtazapine restlessness trazodone vitamin B6 Source Type: research
Molecules, Vol. 29, Pages 676: Direct Immersion & ndash;Solid Phase Microextraction for Therapeutic Drug Monitoring of Patients with Mood Disorders
This article discusses a new method for monitoring drug concentrations in blood samples from patients with mood disorders. The method uses solid-phase microextraction to extract analytes directly from blood samples. It has been adapted to identify the most commonly used drugs in mood disorders, including amitriptyline, citalopram, fluoxetine, paroxetine, sertraline, trazodone, duloxetine, venlafaxine, lamotrigine, quetiapine, olanzapine, and mirtazapine. The analysis is carried out using high-performance liquid chromatography coupled with mass spectroscopy. The proposed DI-SPME/LC-MS method allows for a simple and quick sc...
Source: Molecules - January 31, 2024 Category: Chemistry Authors: Magdalena Świądro-Piętoń Dominika Dudek Renata Wietecha-Pos łuszny Tags: Article Source Type: research
Lithium management of periodic mood fluctuations in behavioural frontotemporal dementia: a case report
This report highlights the potential use of lithium as a mood stabilizer in bvFTD patients with periodic mood fluctuations, refractory to standard treatments. Further research is needed to elucidate the mechanisms underlying lithium’s efficacy in bvFTD and to establish treatment guidelines. (Source: Frontiers in Psychiatry)
Source: Frontiers in Psychiatry - January 8, 2024 Category: Psychiatry Source Type: research
Treatment of REM sleep behavior disorder with trazodone: report of three cases
Journal of Clinical Sleep Medicine, Ahead of Print. (Source: Journal of Clinical Sleep Medicine : JCSM)
Source: Journal of Clinical Sleep Medicine : JCSM - December 29, 2023 Category: Sleep Medicine Authors: Jorden Barrow
Martina Vendrame
1Lehigh Valley Fleming Neuroscience Institute, Lehigh Valley Health Network, Allentown PA
2Morsani College of Medicine, University of South Florida, Tampa FL Source Type: research
Trazodone in the Management of Major Depression Among Elderly Patients with Dementia: A Narrative Review and Clinical Insights
(Source: Neuropsychiatric Disease and Treatment)
Source: Neuropsychiatric Disease and Treatment - December 20, 2023 Category: Psychiatry Tags: Neuropsychiatric Disease and Treatment Source Type: research
TED —trazodone effectiveness in depression: a naturalistic study of the effeciveness of trazodone in extended release formulation compared to SSRIs in patients with a major depressive disorder
Discussion: In summary, the results indicate that trazodone XR is effective in MDD in the “real-world” setting. Its potential superiority over SSRIs in addressing particular symptomatic dimensions should be verified in future studies. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - November 1, 2023 Category: Drugs & Pharmacology Source Type: research
Alzheimer ’s disease and epilepsy: shared neuropathology guides current and future treatment strategies
Epilepsy is a cause of profound disability in patients with Alzheimer’s disease (AD). The risk of being diagnosed with AD increases the risk for epilepsy, and in parallel, a history of epilepsy increases the likelihood of the development of AD. This bi-directional relationship may be due to underlying shared pathophysiologic hallmarks, including decreased cerebrospinal fluid amyloid beta 42 (Aβ42), increased hyperphosphorylated tau protein, and hippocampal hyperexcitability. Additionally, there are practical treatment considerations in patients with co-morbid AD and epilepsy—namely, there is a higher risk of seizures ...
Source: Frontiers in Neurology - October 23, 2023 Category: Neurology Source Type: research
Using pharmacotherapy to address sleep disturbances in autism spectrum disorders
Expert Rev Neurother. 2023 Oct 9. doi: 10.1080/14737175.2023.2267761. Online ahead of print.ABSTRACTINTRODUCTION: Sleep disorders are the second most common medical comorbidity in autism spectrum disorder (ASD), with effects on daytime behavior and functioning, mood and anxiety, and autism core features. In children with ASD, insomnia has also a negative impact on the whole family quality of life. Therefore, treatment of sleep disturbances should be considered as a primary goal in the management of ASD patients, and it is important to clarify the scientific evidence to inappropriate treatments.AREAS COVERED: The authors re...
Source: Expert Review of Neurotherapeutics - October 9, 2023 Category: Neurology Authors: Valeria Mammarella Silvia Orecchio Noemi Cameli Sara Occhipinti Lavinia Marcucci Giuliano De Meo Alice Innocenti Raffaele Ferri Oliviero Bruni Source Type: research
